Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Harvard Bioscience (HBIO) Equity Average (2016 - 2025)

Historic Equity Average for Harvard Bioscience (HBIO) over the last 15 years, with Q3 2025 value amounting to $14.9 million.

  • Harvard Bioscience's Equity Average fell 7752.04% to $14.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.9 million, marking a year-over-year decrease of 7752.04%. This contributed to the annual value of $68.2 million for FY2024, which is 611.17% down from last year.
  • As of Q3 2025, Harvard Bioscience's Equity Average stood at $14.9 million, which was down 7752.04% from $15.3 million recorded in Q2 2025.
  • Harvard Bioscience's 5-year Equity Average high stood at $80.1 million for Q4 2021, and its period low was $14.9 million during Q3 2025.
  • Moreover, its 5-year median value for Equity Average was $73.7 million (2023), whereas its average is $65.9 million.
  • As far as peak fluctuations go, Harvard Bioscience's Equity Average soared by 418.59% in 2021, and later tumbled by 7753.33% in 2025.
  • Harvard Bioscience's Equity Average (Quarter) stood at $80.1 million in 2021, then fell by 10.04% to $72.1 million in 2022, then rose by 2.19% to $73.7 million in 2023, then dropped by 12.69% to $64.3 million in 2024, then crashed by 76.84% to $14.9 million in 2025.
  • Its Equity Average was $14.9 million in Q3 2025, compared to $15.3 million in Q2 2025 and $39.1 million in Q1 2025.